In a recent study published in the journal JAMA Oncology, researchers from Taiwan found that Parkinson disease (PD) is associated with 16 different types of cancer. The study was conducted in an effort to understand the association on an East Asian population, since most investigations aiming to look…
News
A collaboration between the University College London Institute of Neurology, the University of Cambridge and the University of Sheffield found a new link between genetic mutations associated to Parkinson’s disease (PD). The study entitled “The Parkinson’s disease–linked proteins Fbxo7 and Parkin interact to mediate mitophagy” was published…
The U.S. Food and Drug Administration (FDA) on Friday, June 12 announced that it has approved an implantable deep brain stimulation device called the Brio Neurostimulation System, designed to help reduce symptoms associated with Parkinson’s disease and essential tremor, the latter a movement disorder and one of the most common…
Acorda Therapeutics, Inc. recently presented the results of its Phase 2b study of CVT-301, an inhaled levodopa (L-dopa) under development for patients with OFF episodes associated with Parkinson’s disease (PD). OFF episodes cause the re-emergence of PD motor symptoms, including muscle stiffness, impaired movement and tremor. Results from…
Researchers at the University of Pittsburgh School of Medicine and the VA Pittsburgh Healthcare System in Pennsylvania recently revealed that a gene therapy strategy targeting a key protein in Parkinson’s disease pathology – alpha-synuclein – can prevent disease development in a rat model. The study is entitled “…
Researchers at Trinity College Dublin, Ireland, discovered that specific cells in the brain called astrocytes develop an exaggerated reaction to inflammation in the context of neurodegenerative diseases. The study was recently published in The Journal of Neuroscience and is entitled “Astrocytes Are Primed by…
A study recently published in the renowned journal Nature revealed that the different structures adopted by a protein called alpha-synuclein can cause distinct neurodegenerative disorders. The study was led by researchers at the KU Leuven in Belgium and CNRS (Centre National de la Recherche Scientifique) in France…
Melior Discovery, Inc. has recently announced that the United States Patent and Trademark Office (USTPO) granted the company a patent for MLR-1019, its Parkinson’s disease candidate. The patent includes the utilization of this therapeutic to address treatment for dyskinesia linked with L-DOPA therapy in Parkinson’s disease. “This recent patent award will…
Senior Helpers, one of the largest home senior care companies in the United States, recently announced it has been named the exclusive sponsor of online resources for caregiving for the Michael J. Fox Foundation for Parkinson’s Research. The Michael J. Fox Foundation is a nonprofit organization and a leading funder of Parkinson’s disease research throughout the world, committed…
Amarantus BioScience Holdings, Inc, a company that develops diagnostics and treatments for syndromes in the fields of neurology, psychiatry, ophthalmology and regenerative medicine, recently announced the opening of the first clinical site in its Phase 2b trial that will assess the efficacy of eltoprazine in treating patients with Parkinson’s…
Recent Posts
- Exciting family news gives me hope for the future of Parkinson’s
- Think tank outlines 8 key steps to eliminate Parkinson’s
- Short nutrition course may improve life for Parkinson’s patients
- My uncle’s red recliner had a front-row seat to his life with Parkinson’s
- Parkinson’s drug shifts key biomarkers, trial results show